Metabolomic Identification of Exosome-Derived Biomarkers for Schizophrenia: A Large Multicenter Study

• DOI: 10.1093/schbul/sbaa166
• Publication Date: 2020-10-08T19:22:24Z
• Authors: Yang Du; Lei Chen; Xue-Song Li; Xiao-Lin Li; Xiang-Dong Xu; Shao-Bin Tai; Geng-Lin Yang; Quan Tang; Hua Liu; Shu-Han Liu; Shu-Yao Zhang; Yong Cheng
• Keywords: Exosome; Metabolome; Diagnostic biomarker; Pathophysiology

Abstract Exosomes have been suggested as promising targets for the diagnosis and treatment of neurological diseases, including schizophrenia (SCZ), but potential role exosome-derived metabolites in these diseases was rarely studied. Using ultra-performance liquid chromatography-tandem mass spectrometry, we performed first metabolomic study serum-derived exosomes from patients with SCZ. Our sample comprised 385 332 healthy controls recruited 3 clinical centers 4 independent cohorts. We identified 25 perturbed that can be used to classify samples control participants 95.7% accuracy (95% CI: 92.6%–98.9%) training (78 66 controls). These also showed good excellent performance differentiating between test sets participants, accuracies 91.0% 85.7%–96.3%; 107 62 controls), 82.7% 77.6%–87.9%; 104 142 99.0% 97.7%–100%; 96 respectively. Bioinformatic analysis were enriched pathways implicated SCZ, such glycerophospholipid metabolism. Taken together, our findings support a exosomal metabolite dysregulation pathophysiology SCZ indicate strong inform